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Abstract
Purpose: Aberrant microRNA (miRNA) expression is associated with cancer and has potential diagnostic and prognostic
value in various malignancies. In this study, we investigated miRNA profiling as a complementary tool to improve our
understanding of breast cancer (BC) biology and to assess whether miRNA expression could predict clinical outcome of BC
patients.
Experimental Design: Global miRNA expression profiling using microarray technology was conducted in 56 systemically
untreated BC patients who had corresponding mRNA expression profiles available. Results were further confirmed using
qRT-PCR in an independent dataset of 89 ER-positive BC patients homogeneously treated with tamoxifen only. MiR-210
functional analyses were performed in MCF7 and MDA-MB-231 BC cell lines using lentiviral transduction.
Results: Estrogen receptor (ER) status, tumor grade and our previously developed gene expression grade index (GGI) were
associated with distinct miRNA profiles. Several miRNAs were found to be clinically relevant, including miR-210, its
expression being associated with tumor proliferation and differentiation. Furthermore, miR-210 was associated with poor
clinical outcome in ER-positive, tamoxifen-treated BC patients. Interestingly, the prognostic performance of miR-210 was
similar to several reported multi-gene signatures, highlighting its important role in BC differentiation and tumor
progression. Functional analyses in BC cell lines revealed that miR-210 is involved in cell proliferation, migration and
invasion.
Conclusions: This integrated analysis combining miRNA and mRNA expression demonstrates that miRNA expression
provides additional biological information beyond mRNA expression. Expression of miR-210 is linked to tumor proliferation
and appears to be a strong potential biomarker of clinical outcome in BC.
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Introduction
MicroRNAs (miRNAs) are evolutionary conserved, small non-
coding RNA molecules that negatively regulate gene expression.
The single-stranded mature miRNA is 19–25 nucleotides long
and derives from the cleavage of a longer precursor containing a
hairpin structure. Post-transcriptional gene silencing by miRNAs
occurs through the translational inhibition of the targeted
mRNAs or their specific cleavage [1]. Computational analyses
indicate that a unique miRNA can regulate hundreds of genes,
underscoring the potential influence of miRNAs on almost every
cellular pathway. MiRNAs have been shown to regulate various
biological processes such as development, differentiation and
proliferation [2].
Recent studies have demonstrated that mutations in miRNAs or
their aberrant expression are associated with diverse human
diseases, including cancers, suggesting that miRNAs may act as
oncogenes or tumor suppressor genes. MiRNA genes are
frequently located at fragile sites and cancer-associated genomic
regions. Recently, miRNA expression signatures have emerged
from several studies. Iorio et al. identified a signature that could
discriminate normal and breast tumor tissues [3]. Recent findings
have also linked deregulated miRNA expression to tumor
metastasis in breast cancer (BC) cells [4,5]. These results suggest
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e20980that aberrant miRNA expression may be important for the
pathogenesis of this malignancy. In addition to being potential
diagnostic markers, the role of miRNAs in cancer prognosis has
also been highlighted. Indeed, several miRNAs were reported to
be associated with the clinical outcome of patients with chronic
lymphocytic leukaemia [6], lung [7,8] and ovarian cancers [9].
Technologies such as microarray have improved our under-
standing of BC biology, but also disease classification and
prognostication [10–12]. Indeed, gene expression profiling studies
have demonstrated that breast tumors can be divided into at least
four clinically relevant molecular subtypes, each with distinct
disease outcomes: the predominantly estrogen-receptor (ER)-
negative, progesterone-negative, HER-2-negative, basal-like sub-
type, the HER2/neu-positive subtype and at least the two ER-
positive, luminal-like A and B subtypes characterized by their
differences in proliferation rate [11–12]. These results suggest a
biological basis for the clinical heterogeneity of BC.
Our group recently identified a gene expression grade index
(GGI), which mainly reflects tumor proliferation and differentia-
tion [13]. This 97-gene index reclassifies patients with histologic
grade 2 tumors, a clinically problematic tumor type, into two
subgroups with distinct clinical outcomes similar to histological
grade 1 and 3 tumors respectively, improving the accuracy of
tumor grading and therefore its prognostic value [13]. The GGI
can also identify two clinically distinct ER-positive molecular
subtypes, demonstrating the importance of proliferation-related
genes in predicting prognosis in ER-positive BC patients [14].
Finally, proliferation appears to be one of the most prominent
prognostic factor in BC, recapitulating the prognostic power of
several first generation gene prognostic signatures, and highlight-
ing the clinical importance of proliferation-related genes for BC
prognosis [15].
Considering the importance of miRNAs in carcinogenesis, we
sought to investigate miRNA profiling as a complementary tool to
improve our understanding of BC biology and its prognostication.
To this end, we analyzed miRNA and gene expression profiles
from the same BC cohort in order to integrate the information
gained from miRNA profiling with that obtained from the
microarray gene expression profiling of protein-coding genes.
We also thought to identify miRNAs associated with established
clinical/pathologic variables as well as with the previously
reported GGI. Finally, we investigated whether the expression of
miRNAs could predict the clinical outcome of BC patients and
therefore lead to the identification of new prognostic markers.
Results
MiRNA expression profiles from human breast tumors
MiRNA expression profiles were generated from 73 BC fresh-
frozen samples with available mRNA profiling expression data
using an optimized microarray platform for miRNA profiling.
After the application of our quality control criteria, we were able
to analyze 56 of the 73 samples. Patient and tumor characteristics
are summarized in Table 1. In the 56 samples, on average, we
detected the expression of 108 out of the 328 human miRNAs
present on our arrays. The miRNAs detected in at least 90% of the
samples are listed in Table S1.
Breast cancer molecular classification according to
miRNA and mRNA profiling
It has repeatedly been shown that based on mRNA profiling
breast tumors can be classified into four stable molecular subtypes,
with the most prominent discriminators being estrogen receptor
(ER), HER2 and tumor differentiation.
To assess whether miRNAs could recapitulate or even improve
the previously reported molecular classification, we performed a
hierarchical cluster analysis of breast tumors using both miRNAs
and their corresponding protein-coding gene expression profiles.
This analysis was performed in 39 out of the 56 tumor samples for
which both gene expression data of protein-coding genes and
miRNAs were available.
As previously described, protein-coding gene expression profiles
could segregate tumors according to the reported molecular
subtypes [16,17]. Indeed, Figure 1A shows that tumor samples
could be clustered into four main subgroups, predominantly
associated with ER and HER2 status. In contrast, we observed
only a poor concordance with the clustering of the same tumors
based on miRNAs expressions (Figure 1B). Despite the small
sample size, these results suggest that miRNAs may potentially add
information that is complementary to what is generated by mRNA
profiling.
Identification of miRNAs associated with clinical and
pathological characteristics
We then assessed whether relevant clinico-pathological param-
eters such as ER status, tumor size, age and tumor grade, known
Table 1. Summary of patient and tumor characteristics.
Dataset
Variable* OXFU (untreated) OXFT (treated)
Sample size, No. 73 89
Median follow-up time, y 9.23 7.12
No. of relapses 32 30
ER status, No. (%)
Negative 25 (34)
Positive 40 (55) 89 (100)
N/A 8 (11)
Histologic grade, No. (%)
1 8 (11) 18 (20)
2 27 (37) 46 (52)
3 22 (30) 17 (19)
N/A 16 (22) 8 (9)
Lymph node status, No. (%)
Negative 68 (93) 50 (56)
Positive 4 (5) 34 (38)
N/A 1 (1) 5 (6)
Tumor size, No. (%)
#2 cm 43 (59) 34 (38)
.2 cm 29 (40) 55 (62)
N/A 1 (1)
Age, No. (%)
#50 y 29 (40) 12 (13)
.50 y 44 (60) 77 (87)
GG, No. (%)
Low (GG1) 25 (51) 61 (69)
High (GG3) 24 (49) 28 (31)
N/A 24 (49)
*ER=estrogen receptor; N/A=not available; GG=genomic grade.
doi:10.1371/journal.pone.0020980.t001
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differential miRNA expression profiles. It should be noted that
the association between miRNA expression profiles and nodal
status could not be analyzed since our dataset included 93% node-
negative patients.
Student t tests at the nominal p value of 0.05 identified 19 and 20
miRNAs that could segregate breast tumors according to ER status
and tumor grade respectively. These differentially expressed miRNAs
are listed in Table 2. Interestingly, we found only few significant
miRNAsdiscriminatingbreasttumorsbasedontumorsizeandageat
diagnosis. These results suggest that in addition of being associated
with distinct mRNA expression profiles [11], ER status and tumor
grade are also associated with very distinct miRNA profiles,
highlighting the importance of ER and tumor grade in BC biology.
Identification of miRNAs associated with tumor
proliferation and differentiation according to GGI
Given that gene expression grade index (GGI), reflecting tumor
proliferation and differentiation, provides better biological and
clinical information than histological grade [13], we investigated
whether there are miRNAs differentially expressed between high and
low GGItumors, and whether thesemiRNAsare potential regulators
of the genes composing the gene expression grade signature.
Forthispurpose, we contrasted miRNAexpression profilesoflow
and high GGI tumors. This analysis identified 25 miRNAs, which
were differentially expressed between the two subgroups (Table 3).
As expected, 10 of the 25 identified miRNAs were also associated
with histological grade. One of the differentially expressed miRNAs
was the miR-210 (fold change: 3.43, p=0.009), a miRNA that was
recently reported to be associated with hypoxia [18] and with poor
clinical outcome in breast cancer [19].
MiRNAs associated with clinical outcome
MiRNAs potential prognostic value was investigated by
contrasting the expression levels of 328 human miRNAs with
clinical outcome using our systemically untreated BC series with a
median follow-up of 9,2 years. This analysis identified 2 human
miRNAs(miR-210 and miR-148a)that weresignificantlyassociated
with relapse-free survival (RFS) at a p value,0.05. Given its
association with the GGI on one hand and its association with RFS
on the other hand, we decided to concentrate on miR-210.
We first aimed to confirm the differential expression level of miR-
210 between high and low GGI tumors using quantitative real-time
PCR (qRT-PCR). All tumor samples showed detectable expression
levels of miR-210 using qRT-PCR. This contrasted with only 61%
when assessed by microarrays, demonstrating the higher detection
sensitivity of the qRT-PCR technique. Despite this difference in the
detection level between the two techniques, we found a statistically
significant correlation in miR-210 expression between the two
assays (Spearman r=0.7, p=10
26). Furthermore, qRT-PCR
analysis confirmed the statistically significantly differential expres-
sion levels of miR-210 between low and high GGI tumors. High
GGI tumors were associated with 2.73 times higher expression
levels compared to low GGI tumors (p=6.10
24).
Next, in order to further investigate the association between the
GGI and miR-210 targets, we performed a gene set enrichment
analysis using the microarray data used in the original publication
[13]. The resulting p-value computed on 1000 random permuta-
tions was highly significant (0.002), confirming the association
between GGI-low/high subgroups and mir-210 targets. Although
we did not find any gene in common between the miR-210 target
genes and the GGI genes, we observed, when investigating the
networks of these target genes together with the GGI genes with
Ingenuity Pathway Analysis, that the 3 networks representing cell
cycle genes involved a mixture of miR-210 target genes and GGI
genes (Figures S1, S2 and S3).
The fact that high expression levels of miR-210 were associated
with a higher risk of recurrence (p=0.035) concur with recent
findings reported by Camps et al. [19]. We then aimed to confirm
the prognostic value of miR-210 by qRT-PCR. When considered
as a continuous variable in a univariate analysis, miR-210
expression was statistically significantly associated with RFS
(p=2.10
24). Interestingly, when performing subgroup analyses
based on ER status, miR-210 was statistically associated with RFS,
Figure 1. Unsupervised hierarchical clustering analysis using protein-coding genes expression profiles (A) and miRNA expression
(B). Molecular subtypes were defined as described in Desmedt et al. and Wirapati et al. [16,17] according to ER, HER2 and proliferation status. ER2/
HER22 tumors are highlighted in yellow, HER2+ in red, ER+/HER22/low proliferation (luminal A) in green and ER+/HER22/high proliferation (luminal
B) in blue.
doi:10.1371/journal.pone.0020980.g001
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parameters.
A Median expression
No. samples 20 32
Feature ER2 ER+ p value FDR
hsa_miR_224 3.1 1.1 0.001 0.047
hsa_miR_342 76.8 143.1 0.001 0.047
hsa_miR_186 2.1 1.2 0.003 0.128
hsa_let_7c 737.4 1073.4 0.006 0.164
hsa_miR_362 1.4 1 0.006 0.164
hsa_miR_146a 23.3 6.8 0.009 0.215
hsa_miR_345 1.5 1.1 0.011 0.218
hsa_miR_491 5.1 2.3 0.016 0.266
hsa_let_7b 641.5 934.4 0.017 0.266
hsa_let_7a 678.8 948.9 0.024 0.34
hsa_miR_20b 8.1 3.1 0.029 0.34
hsa_miR_181b 12.2 5.2 0.031 0.34
hsa_miR_130b 4.4 2.2 0.033 0.34
hsa_miR_452 1.7 1.1 0.035 0.34
hsa_miR_429 2.1 1.3 0.038 0.34
hsa_miR_181d 3.5 1.8 0.041 0.34
hsa_miR_155 7.9 3.3 0.042 0.34
hsa_miR_148a 22.5 10.5 0.043 0.34
hsa_miR_92 10.4 4.8 0.047 0.351
B Median expression
No. samples 7 17
Feature HG1 HG3 p value FDR
hsa_miR_181b 3.5 19.9 0.001 0.064
hsa_miR_130b 1.4 6.3 0.001 0.064
hsa_miR_146a 4.8 32.4 0.002 0.083
hsa_miR_146b 11.4 40.3 0.002 0.083
hsa_miR_93 27.3 59.3 0.006 0.124
hsa_miR_181a 4.3 19 0.006 0.124
hsa_miR_20b 1.5 10.9 0.006 0.124
hsa_miR_423 1.4 4.4 0.008 0.144
hsa_miR_25 11.1 34.9 0.01 0.152
hsa_miR_106b 3.1 16 0.013 0.173
hsa_miR_186 1 2.4 0.013 0.173
hsa_miR_148a 7.4 25.1 0.017 0.206
hsa_miR_181d 1.5 4.7 0.02 0.215
hsa_miR_128a 1 2 0.032 0.32
hsa_miR_34a 11.5 25.1 0.035 0.32
hsa_miR_363 1 2.4 0.037 0.32
hsa_miR_130a 1.9 5.6 0.039 0.32
hsa_miR_345 1 1.8 0.041 0.32
hsa_miR_362 1 1.7 0.045 0.337
hsa_miR_22 83.3 154.9 0.048 0.338
FDR: False Discovery Rate.
doi:10.1371/journal.pone.0020980.t002
MiR210 a Prognostic and Tumor Proliferation Marker
PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e20980both in the ER-positive (n=32, p=0.004) and the ER-negative
populations (n=20, p=0.008).
Similar results were found in a Kaplan-Meier analysis, for
which patients (N=73) were categorized on the basis of miR-210
median expression value. A statistically significant association was
observed between a high miR-210 expression level (above the
median) and a higher risk of recurrence [HR=4.43 (95% CI:
1.93–10.16), p=5.10
24] (Figure 2A). The Kaplan-Meier curves
for the ER-positive [HR=3.52 (95% CI: 0.99–12.54); p=0.052]
and ER-negative [HR=9.95 (95% CI: 2.77–35.74), p=4.10
24]
populations are illustrated in Figures 2B and 2C, with 55% (22/
40) and 40% (10/25) of the patients assigned to the low-risk group
respectively. MiR-210 thus appears to be associated with worse
clinical outcome both in ER-positive and ER-negative BC.
MiR-210 expression separates histological grade 2 breast
tumors into two groups with distinct clinical outcomes
One of the most interesting findings of the GGI was its ability to
identify two clinically relevant subgroups within the histological
grade 2 tumors. In the current study, we investigated whether
miR-210 expression levels could recapitulate the prognostic ability
of GGI, particularly within the histological grade 2 subgroup. The
normalized expression levels of miR-210 between histological
grades (HG) 1, 2 and 3 and between low and high GGI (GG Low
and GG High) assessed by qRT-PCR are shown in Figure 3A and
3B respectively. As expected, grade 2 tumors spanned the
expression levels of miR-210 of grade 1 and grade 3 tumors. Like
GGI, the expression levels of miR-210 divided grade 2 tumors into
two subgroups with distinct clinical outcomes. Grade 2 tumors
with higher expression levels of miR-210 (above the median) were
associated with worse RFS [HR=7.15 (95% CI: 1.88–27.2),
p=0.004] (Figure 3C), demonstrating that miR-210 recapitulates
the prognostic information of GGI in a similar manner.
As the size of the dataset is small, we aimed to confirm these
results on an independent dataset of 89 ER-positive breast cancer
patients homogeneously treated in the adjuvant setting with
tamoxifen for 5 years and with long follow-up. As in the first
dataset, grade 2 tumors could be separated in two groups of
distinct clinical outcome according to miR-210 expression levels, a
high level of miR-210 being associated with worse RFS
[HR=2.84 (95% CI: 1.09–7.40), p=0.03] (figure 3D), confirming
that the prognostic information of GGI is recapitulated by miR-
210 in a similar manner.
MiR-210 as a prognostic marker in ER-positive tamoxifen
only treated breast cancer patients
Since from our previous work [14] high GGI was associated
with high risk of recurrence after adjuvant tamoxifen therapy in
ER-positive patients, we sought to investigate whether the
expression of miR-210 could also identify two ER-positive
subgroups with distinct clinical outcomes. For this purpose the
expression of miR-210 was evaluated in the second cohort of 89
ER-positive tamoxifen only treated breast cancer patients
(Table 1). We applied similar cut-off to the one defined on the
untreated population in order to separate the population into two
groups, assigning 51% (45/89) of the patients to the low risk
group. As observed in the initial dataset, a statistically significant
survival difference was observed between the two groups
[HR=2.96 (95% CI: 1.42–6.16), p=0.004], a high level of
miR-210 expression being associated with a higher risk of
recurrence than a lower level of miR-210 (Figure 4). MiR-210
remained significant in a multivariate analysis [HR=4.4 (95% CI:
1.65–11.76, p=0.003], together with patient age [HR=4.74
(95% CI: 1.83–12.35, p=0.001] and tumor size [HR=3.53 (95%
CI: 1.28–9.78, p=0.015]. The histological grade, the GGI and the
nodal status were included in the multivariate analysis and have
been substituted by miR-210. Therefore, miR-210 is associated
with poor clinical outcome under tamoxifen treatment.
Comparison of the prognostic accuracy of miR-210 and
recently published prognostic gene expression
signatures
Since proliferation and differentiation, captured by the genomic
grade, seem to be the common denominator for the prognostic
performance of several multi-gene signatures, we assessed whether
miR-210 alone could provide similar information [17].
To address this, we computed time-dependent receiver
operating characteristic curves (ROC) for miR-210 expression
level and several prognostic signatures – the gene expression grade
index (GGI) [13], the 70-gene signature (GENE70) [20], the 76-
gene signature (GENE76) [12] and the estimated 21-gene
recurrence score (RS) [21] - for RFS within 10 years in the ER-
positive patients in both the training dataset and the tamoxifen-
treated breast cancer dataset (Figures 5A and 5B). Gene signature
computation is detailed in material and methods section.
Table 3. Differentially expressed miRNAs associated with the
genomic grade index (GGI).
Median expression
No. samples 17 22
Feature GG Low GG High p value FDR
hsa_miR_185 2 13.4 1.10E-06 0.0001
hsa_miR_221 6.7 33 8.60E-06 0.001
hsa_miR_491 1.6 7.7 3.40E-05 0.002
hsa_miR_422b 1.7 9.4 5.09E-05 0.002
hsa_miR_146a 4.3 30.2 8.66E-05 0.002
hsa_miR_222 1.7 6.4 0.0004 0.01
hsa_miR_181b 3.3 14.6 0.001 0.015
hsa_miR_130b 1.6 5.7 0.001 0.015
hsa_miR_146b 10.4 37.1 0.001 0.019
hsa_let_7i 83 143.5 0.001 0.02
hsa_miR_22 61.7 173.2 0.002 0.023
hsa_miR_155 2.4 9.2 0.004 0.043
hsa_miR_223 2.2 8 0.004 0.043
hsa_miR_379 2.3 6.9 0.004 0.043
hsa_miR_224 1 3.2 0.006 0.059
hsa_miR_210 2.3 7.9 0.009 0.077
hsa_miR_423 1.5 3.6 0.011 0.089
hsa_miR_181a 4.9 13.6 0.011 0.089
hsa_miR_362 1 1.6 0.025 0.184
hsa_miR_346 1.1 1.8 0.027 0.191
hsa_miR_432 1.6 3.4 0.032 0.218
hsa_miR_151 2 4.3 0.034 0.218
hsa_miR_186 1.2 2 0.044 0.264
hsa_miR_191 52.4 109.3 0.046 0.264
hsa_miR_422a 1.4 2.9 0.046 0.264
FDR: False Discovery Rate.
doi:10.1371/journal.pone.0020980.t003
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showssimilar prognostic performance tothemultiplegenes signatures
evaluated in this study. Of interest, similar results were found in an
exploratory analysis in the ER-negative subpopulation of the initial
dataset (Figure 5C). However, these results need further validation.
Involvement of miR-210 in different biological processes
As miR-210 expression is correlated to poor prognosis both in
ER-positive and in ER-negative BC patients, we aimed to
investigate the biological processes regulated by miR-210 and
which may elucidate its function in the aggressive phenotype of high
grade BC. We performed in silico functional analyses of the genes
deregulated upon miR-210 overexpression and repression in two
different BC cell lines. MCF7 cells were used as a model for low
grade ER-positive BC as they are low-proliferating ER-positive cells
which express miR-210 at a level comparable to low grade tumours
according to qRT-PCR (Figure S4). We overexpressed miR-210 (or
a control sequence) in MCF7 cells (MCF7-miR-210 and MCF7-
control respectively) using lentiviral transduction and miR-210
overexpression was confirmed by qRT-PCR. Gene expression
profiling analysis of these cells revealed the upregulation of 897
genes and downregulation of 922 genes upon miR-210 overexpres-
sion (foldchange.2,TableS2).Asa modeltoinvestigatetherole of
miR-210 in ER-negative BC, we used the ER-negative highly-
proliferating MDA-MB-231 cell line which expresses miR-210 at a
high levelashighgrade tumours (FigureS4). WerepressedmiR-210
in MDA-MB-231 cells by overexpressing a sequence complemen-
tary to miR-210 (or a control sequence) using lentiviral transduction
and miR-210 repression was confirmed by qRT-PCR. Gene
expression profiling analysis of these cells revealed that repression
of miR-210 in MDA-MB-231 cells led to the upregulation of 28
genes and downregulation of 58 genes (fold change .2, Table S3).
Interestingly, gene set enrichment analyses investigating Gene
Ontology (GO) categories of the differentially expressed genes
showed that GO categories/pathways such as cell adhesion,
extracellular structure organization, epithelial cell proliferation, cell
division, cell cycle and immune response were significantly over-
represented (p,0.05) (Tables 4A and B).
MiR210 is involved in cell proliferation both in ER-positive
and ER-negative breast cancer cell lines
As gene set expression comparisons revealed that genes involved
in cell cycle and proliferation were deregulated upon miR-
210 overexpression in MCF7 cells and miR-210 repression in
Figure 2. Kaplan-Meier analyses for relapse-free survival according to miR-210 expression levels. (A) Systemically untreated population
(N=73 OXFU); (B) untreated ER-positive population (N=40); (C) untreated ER-negative population (N=25). HR: hazard ratio, CI: confidence intervals.
doi:10.1371/journal.pone.0020980.g002
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proliferative phenotype of high grade tumours. Cell proliferation
assays revealed that miR-210 overexpression led to a statistically
significant increase in MCF7 cell proliferation (MCF7-miR-210)
compared to the control cells (MCF7-control) both in untreated
and in Tamoxifen treated cells according to a two-way Anova
analysis (Figures 6A and 6B). Similarly, MDA-MB-231 prolifer-
ation rate decreased upon miR-210 downregulation (MDA-MB-
231-anti-miR-210) compared to the control cells (MDA-MB-231-
anti-miR-control) (Figure 6C). In conclusion, the association
between miR-210 expression and clinical outcome could rely on
its role as a tumor proliferation regulator both in ER-positive and
ER-negative breast cancer patients.
Role of miR210 in cell migration and invasion
To further define miR-210 role in the aggressive phenotype of
high grade tumors and as genes involved in processes such as cell
adhesion, extracellular matrix structure, extracellular organization
are deregulated upon miR-210 overexpression in MCF7 cells and
miR-210 repression in MDA-MB-231 cells, we aimed to
investigate miR-210 role in cell migration and invasion in the
lentiviral transduced cell lines previously used. As shown in
Figure 7A, miR-210 overexpression in non-invading MCF7 cells
led to cell invasion in a chamber invasion assay. MiR-210
repression in migrating and invading MDA-MB-231 cells led to a
decrease in cell migration compared to the control cells (Figure 7B).
Figure S5 illustrates representative fields of cells which have
acquired migration and invasion capabilities after miR treatment
compared to the control cells. These results suggest that miR-210
prognostic potential could rely on its role as a cell invasion
regulator in ER-positive BC patients and as a regulator of cell
migration in ER-negative breast cancer patients.
Discussion
We optimized a microarray platform which allowed us to
analyze the profiles of the miRNAs expressed in primary human
BC samples from systemically untreated patients. MiRNA
expression profile has been investigated in human BC in two
previous studies comparing tumor samples to normal tissue [3,22].
Here we focused on miRNA profiling on tumor samples only. On
average, we detected 108 out of the 328 human miRNAs present
on our arrays. This falls in the same range as the Blenkiron et al.
study which detected 133 miRNAs in BC samples while analyzing
Figure 3. MiR-210 relative expression according to histological grades and genomic grades. The normalized expression levels of miR-210
between histological grades (HG) 1, 2 and 3 (A) and between low and high GGI (GG Low and GG High) (B) assessed by qRT-PCR. Boxes represent
interquartile range, black bars indicate the median, points represent outliers. p value is based on one-way Anova test. Kaplan-Meier analyses for
relapse-free survival according to miR-210 expression levels in histological grade 2 population. (C) Systemically untreated population (N=27); (D)
Validation ER-positive tamoxifen treated population (N=46) HR: hazard ratio, CI: confidence intervals.
doi:10.1371/journal.pone.0020980.g003
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bead-based method [23].
Through our integrated analysis of combined miRNA and
protein-coding gene profiling, and regarding the sample size, our
results suggest that the molecular subclasses identified by mRNA
profiling (basal/luminal and HER2/Neu) could not be accurately
reproduced by clustering the miRNA profiles. This suggests that
miRNAs might provide additional and complementary informa-
tion regarding BC molecular classification. Interestingly, Blower et
al. came to the same conclusion when comparing the NCI-60
cancer cell line groupings based on miRNAs and mRNAs
expression profiles [24].
In this study, several miRNAs associated with different clinico-
pathologic characteristics were identified. In particular, 19
miRNAs that could segregate ER+ and ER2 breast tumors were
identified. Specifically, within this list, we identified 6 and 5
miRNAs which were also recently shown to be associated with ER
status in the studies published by Blenkirion et al. [23] (miR-342,
let-7a, let-7b, let-7c overexpressed in ER+ tumors, and miR-148a
and miR-155) and Janssen et al. (miR146a, miR-155, miR-224,
miR-362, and miR-155) [25]. We further identified 20 miRNAs
that can distinguish high and low histological grade breast tumors.
Three of them (miR-106b, miR25 and miR-93) were also found to
be associated with the histological grade, as identified by Blenkiron
et al. [23]. These 3 miRNAs were also shown by Janssen et al. to
be associated with the mitotic index and they showed that miR-
106b was the miRNA, which correlated the strongest with
proliferation [25]. Interestingly, Van der Auwera et al. also
reported significant associations between ER status and tumor
grade, but not for tumor size, nodal status, tumor stage or HER2
status [26]. Altogether, our findings reinforce the repeated
observation that, at diagnosis, ER status and tumor grade are
associated with specific miRNA expression profiles, whereas this is
not the case for tumor size and age.
Since our group recently reported that proliferation and
differentiation, captured by GGI, seem to be the main
biological processes associated with BC prognosis and form
the common denominator of different prognostic signatures, we
investigated whether the genes composing the GGI were
Figure 5. MiR-210 shows similar prognostic performance to multiple genes signatures. Time-dependent receiver operating characteristic
curves for miR-210 expression, the gene expression grade index (GGI), the 70-genes signature (GENE70), the 76-genes signature (GENE76) and the
estimated 21-gene recurrence score (ONCOTYPE) for relapse-free survival. (A) Systemically untreated ER-positive population (N=25); (B) ER-positive
tamoxifen-treated population (N=89) and (C) ER-negative untreated population (N=18). Areas under the curves are shown beneath the curves.
doi:10.1371/journal.pone.0020980.g005
Figure 4. Kaplan-Meier analyses for relapse-free survival
according to miR-210 expression levels. Validation ER-positive
tamoxifen treated population (N=89) HR: hazard ratio, CI: confidence
intervals.
doi:10.1371/journal.pone.0020980.g004
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were differentially expressed between low and high gene
expression grade tumors.
Although, several miRNAs would have been potentially
interesting for further investigation, we decided to concentrate
on miR-210 because it was the only miRNA which in addition to
being associated with the GGI, was also associated with prognosis
in our dataset, which is consistent with the recently reported results
by Camps et al. [19].
Interestingly, this miRNA was also shown to be upregulated in
BC cell lines in hypoxic conditions, a key feature of the tumor
microenvironment. Overexpression of miR-210 has also been
reported in various tumors, including breast cancer [3,22].
Furthermore, it has been shown to decrease pro-apoptotic
signaling in a hypoxic environment, suggesting an impact of this
miRNA on tumor formation [27].
The fact that some inconsistencies exist between different
miRNA profiling analyses studies is most likely due to technical
and analytical variations, highlighting the need for standardiza-
tion. Regardless of the technology used, confirmation with another
analytical approach is critical for the validation of findings. We
therefore decided to first validate our findings on the miR-210
using qRT-PCR and found a strong correlation between the
microarray and qRT-PCR results.
Second, we confirmed the association of the GGI and miR-210
target genes using a gene set enrichment analysis. Also, an analysis
of the literature ofthe miR-210 targetgenes revealedthat repression
of those genes in high grade tumors could potentially be responsible
for the proliferative phenotype of these tumors. For example,
ACVR1B (activin receptor 1B), which is a member of the
transforming growth factor beta superfamily that regulates
mammary cell function during development, lactation, and in
cancer has been shown to slow down the growth of breast cancer
cells by inducing G(0)/G(1) cell cycle arrest [28]. Also, CBFA2T1,
also referred to as MTG16, has been shown to have a growth
inhibiting role in breast cancer cell lines [29]. Additionally, recent
evidence indicates that the expression of DICER1, which is the key
enzyme required for the biogenesis of microRNAs and small
interfering RNAs and is essential for both mammalian development
and cell differentiation is associated with hormone receptor status
and cancer subtype in breast tumours and that its downregulation
may be related to the metastatic spread of tumours [30].
Third, we further investigated the prognostic value of miR-210,
for which high expression levels of miR-210 were associated with a
higher risk of recurrence. The prognostic power of miR-210 on the
initial dataset was confirmed using qRT-PCR. We found that this
miRNA was associated with shorter RFS on 40 ER-positive BC
patients. We further demonstrated that this miRNA predicted
Table 4. Examples of significantly impacted biological pathways in MCF7 cells upon miR-210 overexpression (A) and in MDA-MB-
231 cells upon miR-210 repression (B).
A
GO category Description LS permutation p value
GO:0007067 mitosis 0.00001
GO:0051301 cell division 0.00015
GO:0043281 regulation of caspase activity 0.0002
GO:0006916 anti-apoptosis 0.00279
GO:0002418 immune response to tumor cell 0.00501
GO:0016337 cell-cell adhesion 0.00592
GO:0030054 cell junction 0.01132
GO:0051726 regulation of cell cycle 0.01235
GO:0045596 negative regulation of cell differentiation 0.03377
GO:0007346 regulation of mitotic cell cycle 0.04383
GO:0007160 cell-matrix adhesion 0.04499
GO:0007093 mitotic cell cycle checkpoint 0.04942
B
GO category Description LS permutation
p value
GO:0002684 regulation of immune system 0.00001
GO:0016337 cell-cell adhesion 0.00001
GO:0005911 cell-cell junction 0.00001
GO:0050776 regulation of immune response 0.00002
GO:0043062 extracellular structure organization 0.0006
GO:0005201 extracellular matrix structural constituent 0.00067
GO:0000904 cell morphogenesis involved in differentiation 0.00452
GO:0007626 locomotion 0.01268
GO:0007015 actin filament organization 0.01885
GO:0050673 epithelial cell proliferation 0.04524
doi:10.1371/journal.pone.0020980.t004
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only treated patients with ER-positive early BC. Intriguingly, we
showed that this single miRNA had similar prognostic perfor-
mance with the previously published BC multi-gene signatures.
The above multi-gene signatures are mainly informative in ER-
positive rather than ER-negative tumors [17]. The only two multi-
gene signatures reported to carry prognostic information in the
ER-negative subgroup were composed of genes related to immune
response [16,31]. Interestingly, miR-210, apart from being
informative in ER-positive disease, also identified two subgroups
with distinct clinical outcome in patients with ER-negative BC.
However, given the small number of patients, further validation of
this finding on an independent dataset is needed.
We next performed functional analyses to investigate the
association of miR-210 expression and disease outcome. MiR-
210 overexpression in MCF7 cells and repression in MDA-MB-
231 cells induced the deregulation of genes involved in different
biological processes such as cell cycle, cell adhesion and immune
response. Cell proliferation assays revealed that miR-210 overex-
pression enhances MCF7 cell proliferation suggesting that the
prognostic potential of miR-210 may rely on its role in tumor
proliferation both in untreated and tamoxifen-only treated ER-
positive BC. Similarly, MDA-MB-231 cell growth decreased upon
miR-210 repression suggesting that the association between miR-
210 and clinical outcome in ER-negative BC may also rely on its
role as a cell proliferation regulator. Migration and invasion assays
Figure 6. Involvement of miR-210 in cell proliferation. Cell growth curves for MCF7-miR-210 and MCF7-control in untreated (A) and
Tamoxifen-treated (10
27 M) conditions (B). Cell growth curves for MDA-MB-231-anti-miR-210 and MDA-MB-231-control (C).
doi:10.1371/journal.pone.0020980.g006
Figure 7. MiR-210 involvement in cell invasion and migration. MiR-210 overexpression enhances MCF7 cell invasion. Illustration of the
number of invading cells upon miR-210 overexpression compared to the control cells (A). MiR-210 repression enhances MDA-MB-231 cell migration.
Illustration of the number of migrating cells upon miR-210 repression compared to the control cells (B).
doi:10.1371/journal.pone.0020980.g007
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role as a cell invasion regulator in ER-positive BC patients and as
a regulator of cell migration in ER-negative breast cancer patients.
Recent findings demonstrated that e2f transcription factor 3, a
key cell cycle protein, was regulated by miR-210 and that high
frequency of miR-210 gene copy deletions were found in ovarian
cancer patients [18]. Using the same cell lines model, we showed
that miR-210 is involved in the regulation of cell migration and
invasion potentially explaining partially the aggressive phenotype
of high grade tumors. The association of miR-210 expression and
disease outcome could also be due to its anti-apoptotic action that
has been recently identified in cell lines or to its implication in
hypoxia response.
In conclusion, miRNA and mRNA profiling seem to be
complementary tools that can improve our understanding of BC
biology. A single miRNA (miR-210), quantified using a simple and
accurate qRT-PCR assay, showed prognostic performance that
was similar to that of various multi-gene signatures. These results
need further prospective validation.
Materials and Methods
Patient samples
Tissue samples used in this study were provided from the John
Radcliffe Hospital, Oxford, UK. The first population included
fresh-frozen primary tumor samples from 73 BC patients who had
not received any adjuvant systemic treatment. This population is
referred to as OXFU. Protein-coding gene expression profiles,
using the Affymetrix U133A Genechips (Affymetrix, Santa Clara,
CA), were available for 49 of the 73 patients (raw data are
available at the Gene Expression Omnibus (GEO) repository
database [http://www.ncbi.nlm.nih.gov/geo/], accession number
GSE2990) [13].
The second dataset, referred as OXFT, consisted of fresh-frozen
primary tumor samples from 89 ER-positive BC patients
homogeneously treated with tamoxifen only. Protein-coding gene
expression profiles were also available for all patients (GSE6532)
[14].
Table 1 summarizes patient and tumor characteristics from
both populations. Relapse-free survival (RFS) was defined as the
interval between the dates of breast surgery and diagnosis of any
type of relapse (local, regional or distant).
MiRNA microarray hybridization and data normalization
Total RNA from breast tumor samples was isolated using Trizol
method (Invitrogen, Carlsbad, CA). MiRNA labeling and
hybridization on mirVana miRNA Bioarrays V2 were performed
according to the manufacturer’s recommendations using 7.5 mgo f
total RNA and the mirVana miRNA labeling kit (Ambion, Austin,
TX). The Bioarrays used for miRNAs expression profiling
comprise a total of 640 probes targeting 328 human miRNAs
(hsa-miRs), as well as mouse and rat miRNAs, from the miRBase
Sequence Database version 8.0. (http://microrna.sanger.ac.uk/)
[32,33]. Samples with artifacts such as non specific hybridization
or high background intensities have been excluded from analysis
(quality control criteria). Hybridization signals were detected at
532 nm using a GenePix 4000B scanner and quantified by
GenePix Pro 4.0 software (Axon Instruments, Downingtown, PA).
The signal intensity of each spot was calculated by subtracting the
local background from the mean signal. After averaging replicate
spots, a global scaling normalization was applied, as suggested by
Ambion. This normalization consisted of the following steps: 1)
thresholding, for which intensities below the background (set to 2
times the signal of empty spots) were set to 1; 2) scaling, which
involved ranking the intensities of each sample separately and
dividing them by the 30
th intensity value; and 3) log 2
transformation. The normalized intensities were used for further
analyses. Data are available at the Gene Expression Omnibus
(GEO) repository database [http://www.ncbi.nlm.nih.gov/geo/],
accession number GSE28321).
Quantitative real-time PCR (qRT-PCR)
The analysis of miR-210 expression by quantitative real-time
PCR was performed according to the TaqMan MicroRNA Assay
protocol (Applied Biosystems, Foster City, CA). Briefly, 10 ng of
total RNA were reverse-transcribed using the MicroRNA Reverse
Transcription kit and a specific stem-loop primer according to the
manufacturer’s instructions (Applied Biosystems, Foster City, CA).
Real-time PCR was performed on a 7900HT Sequence Detection
System (Applied Biosystems, Foster City, CA). All reactions were
run in triplicate. MiR-210 expression relative to small nucleolar
RNAs RNU44 and RNU48 was calculated using the 2
2DCt
method. This normalized expression level allowed us to determine
the fold changes in miR-210 expression between tumor subgroups.
Cell culture
MCF7 and MDA-MB-231 cells were obtained from the ATCC
and cultured under standard conditions. MiR-210-overexpressing
MCF7 cells (MCF7-miR-210) and MCF7 control cells (MCF7-
control) were cultured under the same conditions as the parental
MCF7 cells. MDA-MB-231 cells in which miR-210 was
downregulated (MDA-MB-231-anti-miR-210) and the corre-
sponding control (MDA-MB-231-control) were cultured under
the same conditions as the parental MDA-MB-231 cells.
Lentiviral production and transduction
Lentiviral vector production was performed as previously
described [34]. Briefly, vesicular stomatitis virus glycoprotein G
(VSV-G) pseudo-typed lentiviral particles were generated by
polyethylene imine (Sigma, St. Louis, MO) co-transfection of
293T cells with three plasmids pMIRNA, pCMVDR8.91 and
pMD.G. pCMVDR8.91 is HIV-derived packaging construct that
encodes the HIV-1 Gag and Pol precursors as well as the
regulatory proteins Tat and Rev. Vesicular stomatitis virus
glycoprotein G (VSV-G) was expressed from pMD.G. pMIRNA
(System Biosciences) is a lentiviral-based vector in which miR-210
precursor sequence (for miR-210 overexpression), a sequence
complementary to miR-210 (for miR-210 repression) or a
scramble sequence (negative control) have been cloned down-
stream of the CMV promoter. This vector contains copepod GFP
as a reporter gene allowing GFP-positive cells sorting by flow
cytometry. Twenty-four 24 h after transient transfection of 293 T
cells, viral supernatants were collected, filtered and concentrated.
For viral transduction, MCF7 and MDA-MB-231 cells were plated
at a density of 10
5 cells/well in 12-wells culture plates and exposed
to lentiviral preparations with MOI 5 in a volume of 500 ml in the
presence of 8 mg/ml polybrene. GFP-positive cells were sorted by
flow cytometry at day 7 after transduction.
Cell proliferation assay
Cell proliferation was determined by 3-(4,5-dimethylthiazole-2-
yl)-2.5 diphenyltetrazolium bromide assay (MTT, Sigma). MCF7-
miR-210 and MCF7-control cells were seeded at a density of 1500
cells per well. MDA-MB-231-anti-miR-210 and MDA-MB-231-
control cells were seeded at a density of 2000 cells per well. At each
time point, 100 ml of 5 mg/ml MTT was added and incubated at
37uC for 3 h and 100 ml DMSO was added to the wells. Every
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measuring the absorbance at 590 nm. Cell growth curves were
calculated as mean values of six replicates after normalization to
the absorbance at day 1. Difference in cell growth was considered
as significant when p,0.05 according to a two-way Anova test.
Cell migration and invasion
Twenty-four well migration and invasion chambers (Cell
Biolabs, San Diego, CA) were used to study cell migration and
invasiveness respectively according to manufacturer’s instructions.
Migratory and invading cells were counted under a light
microscope with five individual fields per insert. Results are
presented as the average of triplicate experiments. Differences in
cell migration and invasion rates were assessed using a Mann
Whitney test and were considered significant when p,0.05.
Protein-coding gene expression profiling
Microarray analysis was performed using the Affymetrix U133A
Genechips following manufacturer’s instructions (Affymetrix, Santa
Clara, CA). Probe quantification and data normalization were
performed as previously [13]. Protein-coding gene expression
profiles (raw data) are available at the Gene Expression Omnibus
(GEO) repository database [http://www.ncbi.nlm.nih.gov/geo/],
accession number GSE25162). Genes were considered as differen-
tially expressed when the fold change between the 2 classes was .2.
Gene Signature Computation
Because we used different gene expression profiling technology
than some of the gene signatures investigated in this study (i.e.
GGI [13], GENE70 [20], GENE76 [12] and Recurrence Score
(RS) [21], we defined gene signature as:
gene signature~
X
i
wixi
,
X
i
wi jj
where xi is the expression of a gene in the gene signature that is
present in the dataset’s platform. wi is either +1o r21 depending
on the sign of the gene-specific weights (coefficients, correlations,
or other measures) from the original. Robust scaling was
performed on each gene signature in order to have the
interquartile range equal to 1 and the median equal to 0 within
each dataset, allowing for comparison between gene signatures. It
is worth mentioning that we computed the low and the high gene
expression grade indices as we did in our original publication [13],
i.e. by defining the cutoff as the middle point between the means of
gene expression grade indices for patients with histological grades
1 and 3.
Statistical analysis
Cluster analyses were conducted to look for natural groupings in
the mRNA and miRNA expression profiles. Unsupervised
hierarchical clustering was performed with uncentered correlation
and average linkage using BRB-ArrayTools software. Molecular
subtypes were defined as described in Desmedt et al. [16] and
Wirapati et al. [17]. In supervised analyses, we assessed whether
clinical parameters were associated with differential miRNA
expression profiles using Student t tests. We also compared low
versus high gene expression grade tumor samples (see Section
Gene Signature Computation). For these comparison analyses, we
only considered miRNAs expressed in at least 20% of the samples.
All p-values were two-tailed and the difference in miRNA
expression was reported as significant when p,0.05. Correlation
of miR-210 expression by microarray and qRT-PCR analysis was
assessed using Spearman’s rank test. For survival analysis, we used
two accuracy measures in order to estimate the relevance of a
variable for survival prediction. First, we used the traditional Cox’s
proportional hazards model [35] to estimate the hazard ratio of
such a variable. Second, we used the time-dependent ROC curve
as defined by Heagerty et al. [36] and its related area under the
curve (AUC). To compare the relevance of two variables for
survival predictions, we compared the hazard ratios by a paired
Student t test. The Kaplan-Meier method was used to estimate the
survival curves. Patients were separated into two groups according
to miR-210 relative expression level, the median value of the initial
dataset being used as the cut-off. The same threshold was used for
the validation dataset in order to avoid overfitting. The survival
data were censored to 10 years. The statistical significance of
global gene expression changes in Gene Ontology (GO) categories
was assessed by LS permutation tests. Statistical analyses were
performed using BRB-ArrayTools software (available at http://
linus.nci.nih.gov/BRB-ArrayTools.html), SPSS 15.0 and Graph-
Pad Prism 5.
Prediction of miRNA target genes
We used the miRanda algorithm for miRNA target genes
prediction. (www.microRNA.org) [37,38].
Association of miRNA target genes
To test the association between miRNA targets and existing gene
signatures, we performed a gene set enrichment analysis [39]. The
class comparison performed to define the gene signature of interest
was done using the gene expression data used in the original
publication. The resulting full ranked list of genes was then used in
combination with the list of targets genes predicted by the miRanda
algorithm (gene set) to compute the enrichment Score (ES). In order
to estimate the null distribution of the ES, the class labels used to
define the signature from the gene expression data were randomly
permutated 1000 times. If the observed ES is significantly higher
that the random ES (permutated p-value,0.05) it meant that the
miRNA targets are significantly associated with the gene signature,
ormore precisely with thebiologicalphenomenon quantifiedbythis
signature.
We performed a gene set enrichment analysis to assess the
association between the Gene expression Grade Index (GGI) and
the target genes of miR-210, following the approach described
above. The ES, defined as the maximum Kolmogorov-Smirnov
ranking sum [39], was significantly higher than ES computed after
random permutations of the labels used to define the GGI from
the original gene expression data, therefore confirming the
association between GGI and mir-210 targets.
Network analyses involving miR-210 target genes and GGI
genes were performed using Ingenuity Pathways Analysis (IPA)
tools (www.ingenuity.com), a web-delivered application that
enables researchers to discover, visualize, and explore molecular
interaction networks in gene expression data.
Supporting Information
Figure S1 Gene network nu1 involving cell cycle genes from the
analysis from IPA including the miR-210 target genes and GGI
genes.
(TIF)
Figure S2 Gene network nu2 involving cell cycle genes from the
analysis from IPA including the miR-210 target genes and GGI
genes.
(TIF)
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analysis from IPA including the miR-210 target genes and GGI genes.
(TIF)
Figure S4 MiR-210 relative expression in MCF7 and MDA-
MB-231 BC cell lines compared to BC samples according to
histological grades (HG) and genomic grades (GG).
(TIF)
Figure S5 MiR-210 involvement in cell invasion and migration.
MiR-210 overexpression enhances MCF7 cell invasion. Illustra-
tion of invading cells upon miR-210 overexpression compared to
the control cells (A). MiR-210 repression enhances MDA-MB-231
cell migration. Illustration of migrating cells upon miR-210
repression compared to the control cells (B).
(TIF)
Table S1 List of the miRNAs detected in at least 90% of the
breast cancer samples.
(XLSX)
Table S2 List of the genes deregulated (fold change FC.2) upon
miR-210 overexpression in MCF7 cells.
(XLSX)
Table S3 List of the genes deregulated (fold change FC.2) upon
miR-210 repression in MDA-MB-231 cells.
(XLSX)
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